Additionally, when tumor cells were treated with single-agent MEK or CDK4 inhibitor, there was a reciprocal activation of the CDK4 or MEK signaling pathways, respectively (Figure 4J), showing a dynamic switching of signaling pathway activation and survival dependencies in the face of pharmacological treatments. Here, MAP2K7 is linked to neoplasm.